专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

SG182187A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS 未知
公开(公告)号：SG182187A1
公开(公告)日：2012-07-30
申请号：SG2012043113
申请日：2008-06-04
申请人： ABBOTT GMBH & CO KG , ABBOTT LAB
发明人： AKRITOPOULOU-ZANZE IRINI , WAKEFIELD BRIAN D , MACK HELMUT , TURNER SEAN C , GASIECKI ALAN F , GRACIAS VIJAYA J , SARRIS KATHY , KALVIN DOUGLAS M , MICHMERHUIZEN MELISSA J , SHUAI QI , PATEL JYOTI R , BAKKER MARGARETHA , TEUSCH NICOLE , KOVAR PETER J , DJURIC STEVAN W , LONG ANDREW J , VASUDEVAN ANIL , HOBSON ADRIAN , ST JOHN MOORE NIGEL , WANG LU , GEORGE DAWN , LI BIQIN , FRANK KRISTINE , JOHNSON ERIC T
摘要： 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORSAbstractThe present invention relates to compounds of formula (1) or pharmaceutical acceptable salts, wherein A, R1,R2, R3 and m, are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as Glycogen Synthase kinase 3 (GSK-3), Rho kinase (ROCK), Janus Kinases (JAK), Ala, PAK4, PLK, CK2, KDR, MK2, JNK I, aurora, pim I and nek 2.No suitable figure

3. 发明专利

CA2689117A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS 未知
公开(公告)号：CA2689117A1
公开(公告)日：2008-12-18
申请号：CA2689117
申请日：2008-06-04
申请人： ABBOTT GMBH & CO KG , ABBOTT LAB
发明人： WAKEFIELD BRIAN D , AKRITOPOULOU-ZANZE IRINI , MACK HELMUT , FRANK KRISTINE , LI BIQIN , VASUDEVAN ANIL , HOBSON ADRIAN , LONG ANDREW J , DJURIC STEVAN W , KOVAR PETER J , JOHNSON ERIC T , TURNER SEAN C , GEORGE DAWN , GASIECKI ALAN F , WANG LU , ST JOHN MOORE NIGEL , MICHMERHUIZEN MELISSA J , GRACIAS VIJAYA J , SARRIS KATHY , KALVIN DOUGLAS M , SHUAI QI , PATEL JYOTI R , BAKKER MARGARETHA , TEUSCH NICOLE
IPC分类号： C07D403/04 , C07D413/04 , C07D417/04
摘要： The present invention relates to compounds of formula (I) or pharmaceutic al acceptable salts, wherein A, R1, R2, R3 and m, are defined in the descrip tion. The present invention relates also to methods of making said compounds , and compositions containing said compounds which are useful for inhibiting kinases such as Glycogen Synthase kinase 3 (GSK-3), Rho kinase (ROCK), Janu s Kinases (JAK), AKT, PAK4, PLK, CK2, KDR, MK2, JNK1, aurora, pim 1 and nek 2.

5. 发明专利

JP2014074057A 5-heteroaryl substituted indazoles as kinase inhibitors 审中-公开
标题翻译：作为激酶抑制剂的5-HETEROARYL取代的吲哚美辛
公开(公告)号：JP2014074057A
公开(公告)日：2014-04-24
申请号：JP2013266989
申请日：2013-12-25
申请人： Abbvie Inc , アッヴィ・インコーポレイテッド , Abbott Gmbh & Co Kg , アボットゲーエムベーハーウントカンパニーカーゲー
发明人： IRINI AKRITOPOULOU-ZANZE , WAKEFIELD BRIAN D , MACK HELMUT , SEAN C TURNER , ALAN F GASIECKI , GRACIAS VIJAYA J , SARRIS KATHY , KALVIN DOUGLAS M , MICHMERHUIZEN MELISSA J , SHUAI QI , PATEL JYOTI R , BAKKER MARGARETHA , NICOLE TEUSCH , ERIC F JOHNSON , KOVAR PETER J , STEVAN W DJURIC , ANDREW J LONG , ANIL VASUDEVAN , ADRIAN HOBSON , NIGEL ST JOHN MOORE , WANG LU , DAWN GEORGE , LI BIQIN , KRISTINE FRANK
IPC分类号： C07D401/04 , A61K31/4155 , A61K31/4178 , A61K31/4192 , A61K31/422 , A61K31/423 , A61K31/427 , A61K31/429 , A61K31/437 , A61K31/4439 , A61K31/454 , A61K31/4709 , A61K31/4725 , A61K31/496 , A61K31/4985 , A61K31/506 , A61K31/519 , A61K31/5377 , A61K31/541 , A61K31/551 , A61P3/04 , A61P3/10 , A61P5/00 , A61P9/10 , A61P11/00 , A61P15/00 , A61P17/14 , A61P25/00 , A61P25/16 , A61P25/18 , A61P25/24 , A61P25/28 , A61P27/02 , A61P27/06 , A61P35/00 , A61P35/02 , A61P43/00 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D409/04 , C07D413/04 , C07D413/14 , C07D417/04 , C07D417/08 , C07D471/04 , C07D487/04 , C07D513/04
CPC分类号： C07D403/04 , C07D413/04 , C07D417/04
摘要： PROBLEM TO BE SOLVED: To provide compounds which inhibit specific combinations of kinases or target kinase pathways.SOLUTION: The present invention relates to 5-substituted indazole compounds represented by the specified general formula (I) or pharmaceutically acceptable salts of the compounds. The present invention relates also to methods of making the compounds, and to compositions containing the compounds useful for inhibiting kinases such as Glycogen Synthase kinase 3 (GSK-3), Rho kinase (ROCK), Janus Kinases (JAK), AKT, PAK4, PLK, CK2, KDR, MK2, JNK1, aurora, pim1 and nek2.
摘要翻译：要解决的问题：提供抑制激酶或靶激酶途径的特异性组合的化合物。解决方案：本发明涉及由指定的通式（I）表示的5-取代的吲唑化合物或化合物的药学上可接受的盐。本发明还涉及制备该化合物的方法，以及含有可用于抑制激酶例如糖原合酶激酶3（GSK-3），Rho激酶（ROCK），Janus激酶（JAK），AKT，PAK4， PLK，CK2，KDR，MK2，JNK1，极光，pim1和nek2。

6. 发明专利

JP2006001923A Peptide drug having antiangiogenic effect 有权
标题翻译：肽类药物具有抗炎作用
公开(公告)号：JP2006001923A
公开(公告)日：2006-01-05
申请号：JP2005134080
申请日：2005-05-02
申请人： Abbott Lab , アボット・ラボラトリーズAbbott Laboratories
发明人： HENKIN JACK , HAVIV FORTUNA , BRADLEY MICHAEL F , KALVIN DOUGLAS M , SCHNEIDER ANDREW J
IPC分类号： A61K38/00 , C07K7/06 , A61P3/10 , A61P9/00 , A61P17/06 , A61P19/02 , A61P27/02 , A61P29/00 , A61P31/00 , A61P31/04 , A61P35/00 , C07K7/02 , C07K14/78
CPC分类号： C07K14/78 , A61K38/00
摘要： PROBLEM TO BE SOLVED: To provide a new antiangiogenic compound useful to treat a condition which is occasioned or worsened by angiogenesis. SOLUTION: The compound is a peptide having the formula: A 0 -A 1 -A 2 -A 3 -A 4 -A 5 -A 6 -A 7 -A 8 -A 9 -A 10 (wherein A 0 is selected from hydrogen and an acyl group; A 10 is a hydroxy group or an amino acid amide; and A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , A 8 , and A 9 are each an aminoacyl residue such as pyroGlu-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH3). COPYRIGHT: (C)2006,JPO&NCIPI
摘要翻译：要解决的问题：提供一种新的抗血管生成化合物，可用于治疗由血管发生引起或恶化的病症。解决方案：该化合物是具有下式的肽：A 0 -A -A 2 / SB> -A 4 -A 5 -A 6 -A 7 -A 8 < 其中A 0 选自氢和酰基; A 10 SB>是羟基或氨基酸酰胺; A 1 ，A 2 ，A 3 ，A SB>，A 5 ，A 6 ，A 7 ，A 8 / SB>各自为氨酰基残基，如pyroGlu-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH3）。版权所有（C）2006，JPO＆NCIPI

7. 发明专利

JP2006232840A Peptide pharmaceutical having neovascularization activity 审中-公开
标题翻译：具有新鲜血液活性的肽药物
公开(公告)号：JP2006232840A
公开(公告)日：2006-09-07
申请号：JP2006065255
申请日：2006-03-10
申请人： Abbott Lab , アボット・ラボラトリーズAbbott Laboratories
发明人： HENKIN JACK , HAVIV FORTUNA , BRADLEY MICHAEL F , KALVIN DOUGLAS M , SCHNEIDER ANDREW J
IPC分类号： A61K38/00 , C07K7/06 , A61P9/00 , A61P17/06 , A61P19/02 , A61P27/02 , A61P31/00 , A61P31/04 , A61P35/00 , C07K14/78
CPC分类号： C07K14/78 , A61K38/00
摘要： PROBLEM TO BE SOLVED: To provide a compound having the activity useful for treating symptoms caused or aggravated by neovascularization, and to provide a pharmaceutical composition containing the compound. SOLUTION: The compound is a peptide of the formula:A 0 -A 1 -A 2 -A 3 -A 4 -A 5 -A 6 -A 7 -A 8 -A 9 -A 10 ( wherein, A 0 is H or an acyl; A 10 is OH or an amino acid amido; and A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , A 8 and A 9 are each a specific aminoacyl residue ). COPYRIGHT: (C)2006,JPO&NCIPI
摘要翻译：待解决的问题：提供具有可用于治疗由新生血管形成引起或加重的症状的活性的化合物，并提供含有该化合物的药物组合物。解决方案：该化合物是下式的肽：A 0 -A -A 2 / SB> -A 4 -A 5 -A 6 -A 7 -A 8 < / SB> -A -A 10 （其中，A 0 是H或酰基; A SB < 是OH或氨基酸酰氨基; A 1 ，A 2 ，A 3 ，A 4 A，SB SB 7，SB SB 8，SB SB 8，SB SB 8，SB SB 8，SB SB 8，SB 8，特定的氨基残基）。版权所有（C）2006，JPO＆NCIPI

8. 发明申请

WO0138347A3 PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY 审中-公开
标题翻译：具有抗血管生成活性的肽
公开(公告)号：WO0138347A3
公开(公告)日：2001-11-29
申请号：PCT/US0032217
申请日：2000-11-22
申请人： ABBOTT LAB
发明人： HAVIV FORTUNA , HENKIN JACK , BRADLEY MICHAEL F , KALVIN DOUGLAS M , SCHNEIDER ANDREW J
IPC分类号： A61K38/00 , A61P9/00 , A61P17/06 , A61P19/02 , A61P27/02 , A61P35/00 , C07K1/22 , C07K7/06 , C07K14/705 , C07K14/78 , A61K38/39
CPC分类号： C07K7/06 , A61K38/00
摘要： Peptides of formula (I) Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11, are useful for inhibiting angiogenesis. Also disclosed are angiogenesis-inhibiting compositions and methods of inhibiting angiogenesis in a mammal.
摘要翻译：式（I）Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11的肽可用于抑制血管生成。还公开了血管生成抑制组合物和抑制哺乳动物血管生成的方法。

9. 发明专利

PT1232183E PEPTIDOS POSSUINDO ACTIVIDADE ANTI-ANGIOGENICA 未知
公开(公告)号：PT1232183E
公开(公告)日：2006-06-30
申请号：PT00982219
申请日：2000-11-22
申请人： ABBOTT LAB
发明人： FORTUNA HAVIV , HENKIN JACK , BRADLEY MICHAEL F , KALVIN DOUGLAS M , SCHNEIDER ANDREW J
IPC分类号： A61K38/00 , A61P9/00 , A61P17/06 , A61P19/02 , A61P27/02 , A61P35/00 , C07K1/22 , C07K7/06 , C07K14/705 , C07K14/78 , A61K38/39

10. 发明专利

PE20030302A1 PEPTIDOS CON ACTIVIDAD ANTI-ANGIOGENICA 未知
公开(公告)号：PE20030302A1
公开(公告)日：2003-03-27
申请号：PE2002000665
申请日：2002-07-25
申请人： ABBOTT LAB
发明人： AVIV FORTUNA , KALVIN DOUGLAS M , HENKIN JACK , BRADLEY MICHAEL F
IPC分类号： A61K38/00 , A61P9/00 , A61P35/00 , C07K5/068 , C07K7/06
摘要： SE REFIERE A PEPTIDOS DE FORMULA A0-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10; A0 ESTA AUSENTE, N-ACETILO, N-ACETILAZETIDIN-2-CARBONILO, N-ACETILAZETIDIN-3-CARBONILO, N-ACETILNIPECOTILO, N-ACETILPIPERIDIN-4-ACETILO, N-ACETILPROLILO; A1 ES D-ALANILO, (1R,3S)-1-AMINOCICLOPENTAN-3-CARBONILO, (1S,4R)-1-AMINOCICLOPENT-2-EN-4-CARBONILO, 1-AMINO-1-CICLOPROPANCARBONILO, ENTRE OTROS; A2 ES [(1S,3R)-1-AMINOCICLOPENTAN-3-CARBONILO], [(1R,4S)-1-AMINOCICLOPENT-2-EN-4-CARBONILO, [(1S,4R)-1-AMINOCICLOPENT-2-EN-4-CARBONITRILO, ENTRE OTROS; A3 ES ASPARAGINILO, GLUTAMINILO, ISOLEUCILO, VALILO; A4 ES D-ALOISOLEUCILO, D-LEUCILO, D-FENICILAMINIL(S-METIL); A5 ES ALOTREONILO, ASPARTILO, 4-HIDROXIPROLILO. SERILO, TREONILO, TREONIL(O-ACETILO); A6 ES ALOTREONILO, GLUTAMINILO, 4-HIDROXIPROPILO, ENTRE OTROS; A7 ES ISOLEUCILO, PROLILO; A8 ES ARGINILO, GLUTAMINILO, ORNITILO; A9 ES PROLILO; A10 ES D-ALANILAMIDA, D-LISIL(N-EPSILON-ACETIL)AMIDA, ENTRE OTROS; CUADO A0 ESTA AUSENTE, A1 ES N-METILPROLILO; CUANDO A1 ES SARCOSILO A0 NO ES ACETILO; A2 NO ES ASPARAGINILO, GLUTAMINILO, GLICICLO; A4 NO ES D-ISOLEUCILO, A5 NO ES ALOTREONILO, SERILO, TREONILO; A6 NO ES GLUTAMINILO, NORVALILO, SERILO, TRIPTILO; A8 NO ES ARGINILO; A10 NO ES D-ALANILAMIDA, ETILAMIDA. LOS COMPUESTOS INHIBEN LA MIGRACION DE CELULAS ENDOTELIALES Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE ANGIOGENESIS

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式